Vivo Bio Tech Limited (BOM:511509)
India · Delayed Price · Currency is INR 24.03
0.00 (0.00%)
At close: Jun 19, 2026
Vivo Bio Tech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 533.35 | 466.73 | 454.51 | 522.3 | 513.91 |
Other Revenue | - | - | 0 | - | - |
| 533.35 | 466.73 | 454.51 | 522.3 | 513.91 | |
Revenue Growth (YoY) | 14.27% | 2.69% | -12.98% | 1.63% | -0.74% |
Cost of Revenue | 81.27 | 61.07 | 41.52 | 70.67 | 116.5 |
Gross Profit | 452.08 | 405.65 | 412.99 | 451.64 | 397.41 |
Selling, General & Admin | 237.59 | 200.56 | 202.09 | 236.62 | 239.27 |
Operating Expenses | 343.85 | 290.73 | 295 | 329.27 | 313.73 |
Operating Income | 108.22 | 114.93 | 118 | 122.36 | 83.67 |
Interest Expense | -58.49 | -75.04 | -77.78 | -76.51 | -39.93 |
Interest & Investment Income | - | 1.9 | 0.39 | 0.36 | 0.98 |
Other Non Operating Income (Expenses) | 4.41 | -0 | - | 0 | 0 |
EBT Excluding Unusual Items | 54.15 | 41.78 | 40.61 | 46.21 | 44.72 |
Gain (Loss) on Sale of Assets | - | 46.15 | - | - | - |
Other Unusual Items | -6.05 | - | - | - | - |
Pretax Income | 48.1 | 87.93 | 40.61 | 46.21 | 44.72 |
Income Tax Expense | 65.19 | 15.1 | 15.34 | 19.72 | 22.71 |
Net Income | -17.09 | 72.83 | 25.26 | 26.49 | 22.02 |
Net Income to Common | -17.09 | 72.83 | 25.26 | 26.49 | 22.02 |
Net Income Growth | - | 188.27% | -4.64% | 20.33% | -61.26% |
Shares Outstanding (Basic) | 21 | 15 | 15 | 15 | 14 |
Shares Outstanding (Diluted) | 21 | 15 | 17 | 15 | 14 |
Shares Change (YoY) | 36.27% | -8.33% | 12.53% | 4.66% | 4.44% |
EPS (Basic) | -0.82 | 4.76 | 1.70 | 1.79 | 1.56 |
EPS (Diluted) | -0.82 | 4.76 | 1.51 | 1.78 | 1.56 |
EPS Growth | - | 215.23% | -15.17% | 14.33% | -62.84% |
Free Cash Flow | -25.07 | -104.42 | 75.72 | 108.36 | -344.7 |
Free Cash Flow Per Share | -1.20 | -6.83 | 4.54 | 7.31 | -24.34 |
Gross Margin | 84.76% | 86.91% | 90.86% | 86.47% | 77.33% |
Operating Margin | 20.29% | 24.62% | 25.96% | 23.43% | 16.28% |
Profit Margin | -3.20% | 15.60% | 5.56% | 5.07% | 4.28% |
Free Cash Flow Margin | -4.70% | -22.37% | 16.66% | 20.75% | -67.07% |
EBITDA | 214.49 | 184.23 | 189.98 | 194.05 | 142.99 |
EBITDA Margin | 40.22% | 39.47% | 41.80% | 37.15% | 27.82% |
D&A For EBITDA | 106.27 | 69.3 | 71.98 | 71.68 | 59.32 |
EBIT | 108.22 | 114.93 | 118 | 122.36 | 83.67 |
EBIT Margin | 20.29% | 24.62% | 25.96% | 23.43% | 16.28% |
Effective Tax Rate | 135.53% | 17.18% | 37.78% | 42.67% | 50.77% |
Revenue as Reported | 537.76 | 514.77 | 454.9 | 522.66 | 514.89 |
Advertising Expenses | - | 0.39 | 2.79 | 2.8 | 1.22 |